2015-11-12T08:32:47-00:00 2014-12-31 KPMG LLP 1918 8th Avenue Suite 2900 Seattle WA 98101 990 2014-01-01 910653422 Benaroya Research Institute at Virginia Mason BENA 2063426500 1201 Ninth Avenue Seattle WA 981012795 Homer W Lane Jr Executive DirectorCFO 2015-11-03 true Sue Robison 2069134000 2014 2016-02-25 16:41:14Z Gerald Nepom MD PhD 1201 Ninth Avenue Seattle WA 98101 61520797 false X http://www.benaroyaresearch.org X 1956 WA To conduct and encourage high quality medical, surgical, and scientific research and research training in disease and problems of medical importance. 20 15 328 9 0 44973133 54174085 6122655 6639555 88984 164405 346008 350163 51530780 61328208 6179570 17599162 0 23665207 25135170 0 0 15546338 19170074 45391115 61904406 6139665 -576198 82770690 85390333 40055412 43346845 42715278 42043488 X See Schedule O false false 18890380 13183705 Immune Tolerance Network Program. See Schedule O. 12047182 2736119 Translational Program. See Schedule O. 6169555 428014 Diabetes Program. See Schedule O. 14382847 1251324 6639555 51489964 true true false true false false false false false true true true false false false false true false false false true true false false false false false true false true true false false true false false false false false false false true false false false false true false false false false true 90 0 true 328 true false false false false false false false false false false X 20 15 false false false false true true true true true false false true true true true true true true true false WA X Homer W Lane Jr Executive DirectorC 2063426508 1201 Ninth Avenue Seattle WA 981012795 Carla Greenbaum MD Director 040.00 X 211149 0 29898 Gerald Nepom MD PhD Ex Officio, Director 040.00 X X 512545 0 43088 Joyce Lammert MD PhD Director 001.00 050.00 X 0 580352 122566 John Corman MD Director 001.00 050.00 X 0 484030 68007 Gary Kaplan MD Director 001.00 054.00 X 0 1470727 2092430 Tom Cohen Director 001.00 X 0 0 0 Rebecca Campbell Director 001.00 X 0 0 0 Kristi Pangrazio Director, Chairman 001.00 X X 0 0 0 Margaret Morrow Director, Secretary 001.00 X X 0 0 0 Steven Gillis PhD Director 001.00 X 0 0 0 Frank Dvorak PhD Director 001.00 X 0 0 0 Trish Markey Director 001.00 X 0 0 0 Edward Drosdick Director, Treasurer 001.00 X X 0 0 0 David Williams Director 001.00 X 0 0 0 Ditman Johnson Director 001.00 X 0 0 0 Michael Gallatin Director 001.00 X 0 0 0 Jessica Muffett Director 001.00 X 0 0 0 Carla DewBerry Director, Vice-Chair 001.00 X X 0 0 0 Ann Sobil Director 001.00 X 0 0 0 Christopher Wilson MD Director 001.00 X 0 0 0 Homer Lane Jr Executive Director and Chief Financial Officer 040.00 X 319692 0 21394 Jane Buckner MD Research Member 040.00 X 225896 0 25892 William Kwok PhD Research Member 040.00 X 207910 0 28652 Steven Ziegler PhD Research Member 040.00 X 178278 0 23396 Thomas Wight PhD Research Member 040.00 X 161933 0 37808 Lynn Rose PhD Director Scientific Administration 040.00 X 175329 0 23134 1992732 2535109 2516265 36 false true false KPMG LLP 1918 Eighth Ave Suite 2900 Seattle WA 98101 Auditing Consulting 113972 DNA Brand Mechanics 1301 Fifth Ave Suite 2600 Seattle WA 98101 Consulting 180865 Aspect Software Inc PO Box 894675 Los Angeles CA 90189 Consulting 122705 Insight Global LLC PO Box 198226 GA GA 30384 Consulting 106178 4 5075000 42166205 6932880 147625 54174085 Commercial Studies 621500 3412077 3412077 Core services 621500 3227478 3227478 6639555 164405 164405 542752 192589 350163 350163 350163 61328208 6639555 514568 15306919 15306919 0 2292243 2292243 0 2038108 1221969 816139 0 16670043 12724620 3945423 1405104 1014521 390583 3738990 2699645 1039345 1282925 926304 356621 0 26239 26239 93798 93798 0 0 1906657 1120536 786121 297252 297252 194207 78285 115922 1214790 271907 942883 0 2722498 2403867 318631 297778 264578 33200 0 115644 95466 20178 830874 731170 99704 0 3232688 2618059 614629 42774 42774 Supplies 5954408 5873296 81112 Other Purchased Services 269993 195506 74487 Patient Costs 1042201 1042201 Research Participants Fee 434663 434637 26 493610 174235 319375 61904406 51489964 10414442 0 7908388 9549793 738315 747735 9220049 11311167 389852 314740 302375 505401 67900499 35596413 32861320 32304086 8350523 8505508 21942003 21252233 1057865 899670 82770690 85390333 7491442 10220796 2617480 4074559 10075000 9755000 19871490 19296490 40055412 43346845 X 23916255 24026666 9702544 8864453 9096479 9152369 42715278 42043488 82770690 85390333 -576198 -140592 45000 X false true X true true true X Virginia Mason Medical Center Seattle WA 29756050 34328409 38329362 44973133 54219085 201606039 29756050 34328409 38329362 44973133 54219085 201606039 29779658 171826381 1644044 1724806 560734 642011 707157 5278752 2423158 2391006 4701834 6122655 6639555 22278208 229162999 0.74980 0.72700 X 0.00000 0.00000 RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED X 119335 19500 138835 61904406 1056494119 61904406 1056632954 1000000 1000000 250000 250000 1000000 1000000 1000000 1000000 4000000 6000000 222311 133874 122035 138835 617055 250000 250000 250000 250000 1000000 1500000 122311 127874 114035 119335 483555 false false false false false false false false false false false II-A A Benaroya Research Institute at Virginia Mason, EIN 91-0653422, 1201 Ninth Avenue, Seattle, WA 98101. Non-electing member. 0 Lobbying Expenditures. Excess Lobbying Expenditures 0. II-A A continued Virginia Mason Health System, EIN 91-1351110, 1100 Ninth Avenue, Seattle, WA 98101. Non-electing member. 0 Lobbying Expenditures. Excess Lobbying Expenditures 0. II-A A continued Virginia Mason Institute, EIN 26-3763656, 1100 Ninth Avenue, Seattle, WA 98101. Non-electing member. 0 Lobbying Expenditures. Excess Lobbying Expenditures 0. II-A A continued Virginia Mason Medical Center, EIN 91-0565539, 1100 Ninth Avenue, Seattle, WA 98101. Electing Member. Grassroots Lobbying Expenditures 119,335. Direct Lobbying Expenditues 19,500. Excess Lobbying Expenditures 0. Tax year ending December 31, 1998 was the first year in which Virginia Mason Medical Center made the election under Section 501h. The election was not revoked before the start of the tax year ending December 31, 2014. false false true true 756906 756906 48213776 21049090 27164686 196862 196862 18638013 14350461 4287552 94942 94942 32304086 Financial derivatives and other financial products Closely-held equity interests Interest in Net Assets of Virginia Mason Health System 21252233 F 21252233 Federal income taxes 61232616 -140592 45000 -95592 61328208 61328208 61904406 61904406 61904406 East Asia and the Pacific Conferences Medical Research 3710 Europe Including Iceland and Greenland Conferences Medical Research 23320 27030 27030 Europe Including Iceland and Greenland Medical Research 1954683 Wire Transfer North America Medical Research 244795 Wire Transfer East Asia and the Pacific Medical Research 92764 Wire Transfer 15 false false false false false false Part I Line 2 Subrecipient Monitoring Policy - medical research sub awards - BRI has formal policies and procedures to assure full compliance with applicable policies and laws governing Federal Grants. The Subrecipient Monitoring policy provides assurance that subrecipients comply with Federal Grant regulations. This policy sets the criteria to establish eligibility of subrecipients to provide annual audited financial reports and the annual OMB single audit report that identify compliance with federal laws and regulations. The reports are analyzed with emphasis on auditors assessement of subrecipient internal controls and a standardized Risk Assessment is presented to management on each subrecipient. A Management Letter is issued to each subrecipient showing any findings on their OMB single audit report, and measurements are set for increased monitoring when an elevated level of risk is established. Management has communicated with an educated administrative staff regarding implementation of this policy. The Director of Grants and Contracts is responsible for monitoring subrecipient adherence to financial regulations. The principal investigator is responsible for overseeing the satisfactory performance of the sub-award to ensure that goals are achieved. If there are unusual or unforeseen items, these will be investigated. Part I Line 3f The expenditures were actual expenses incurred in the region based on individual expense reports and tracking of expenditures by grant or department on the accrual basis of accounting. Part II Line 1 The expenditures were expenses incurred in the region based on award goals on the accrual basis of accounting. true Adaptive Biotechnologies 1551 Eastlake Ave S Suite 200 Seattle WA 98102 270907024 43384 Medical Research Ann & Robert H Lurie Children's Hospital of Chicago 225 East Chicago Ave No 205 Chicago IL 606112991 362170833 501c3 30155 Medical Research Arkansas Children's Hospital Research Institute Slot 663 One Childrens Way Little Rock AR 722023591 710694931 501c3 156665 Medical Research Asthma Inc 9725 3rd Aven NE Suite 500 Seattle WA 98115 237219813 501c3 35064 Medical Research Blood Systems Research Institute 270 Masonic Ave San Francisco CA 94118 860098929 501c3 87730 Medical Research The Brigham and Women's Hospital Inc 101 Huntington Avenue Suite 300 Boston MA 02199 042312909 501c3 92628 Medical Research California Institute of Technology 1200 E California Blvd Pasadena CA 91125 951643307 501c3 45612 Medical Research Cedars-Sinai Medical Center 8700 Beverly Blvd Suite 1150 Los Angeles CA 900481804 951644600 501c3 186725 Medical Research Childrens Hospital Los Angeles 4650 Sunset Blvd Los Angeles CA 90027 951690977 501c3 21152 Medical Research Children's Mercy Hospital 2401 Gillham Road Kansas City MO 64101 440605373 501c3 19046 Medical Research Columbia University PO Box 29789 General Post Office New York NY 100879789 135598093 501c3 35252 Medical Research Creighton University 2500 California Plaza Omaha NE 68178 470376583 501c3 13927 Medical Research Duke University PO Box 602651 Charlotte NC 282602651 560532129 501c3 207116 Medical Research Emory University 101 Woodruff Circle - 7126 WMRB Atlanta GA 30322 580566256 501c3 197523 Medical Research Feinstein Institute for Medical Research 972 Brush Hollow Rd Westbruy NY 11590 112673595 501c3 60158 Medical Research Fred Hutchinson Cancer Research Center 1100 Fairview Ave N Seattle WA 98109 237156071 501c3 62208 Medical Research Icahn School of Medicine at Mount Sinai One Gustave L Levy Place Box 3500 New York NY 100296574 136171197 501c3 174353 Medical Research Indiana University 400 3 7th St Poplars Room 501 Bloomington IN 47405 356001673 501c3 45930 Medical Research John Hopkins University 12529 Collections Center Drive Chicago IL 60693 520595110 501c3 319979 Medical Research Lab Key Software 617 Eastlake Ave E 400 Seattle WA 98109 208266728 119134 Medical Research La Jolla Institute for Allergy & Immunology 9420 Athena Circle La Jolla CA 92037 330328688 501c3 54118 Medical Research Louisana State University Health Sciences Center at Shreveport 1501 Kings Highway Shreveport LA 711303932 720702002 Louisana 15277 Medical Research Massachusetts General Hospital 55 Fruit Street Research Management Boston MA 02114 042697983 501c3 3971129 Medical Research National Jewish Health 1400 Jackson Street M213 Denver CO 80206 742044647 501c3 44054 Medical Research New York University-School of Medicine PO Box 415026 Boston MA 022415026 135562308 501c3 27232 Medical Research Northwestern University 645 N Michigan Ave Suite 530 Chicago IL 60611 362167817 501c3 35107 Medical Research Norton Neurosciences Institute 224 East Broadway 7th Floor Louiseville KY 402022025 611276316 501c3 8910 Medical Research Oklahoma Medical Research Foundation 825 NE 13th Street Oklahoma City OK 73104 730580274 501c3 104459 Medical Research The Research Insitute at Nationwide PO Box 715245 Columbus OH 432715245 316056230 501c3 107821 Medical Research Rockefeller University 1230 York Ave New York NY 100656307 131624158 501c3 115948 Medical Research Rogosin Institute 504 East 74th St 5th Floor New York NY 100214782 133184198 501c3 63560 Medical Research Rutgers the State University of New Jersey 3 Rutgers Plaza New Brunswick NJ 089018559 226001086 501c3 257701 Medical Research Sanford Research 2301 E 60th St N Sioux Falls SD 57104 460450378 501c3 13513 Medical Research Seattle Childrens Hospital PO Box 24728 Seattle WA 981240728 910564748 501c3 953537 Medical Research South Suburban Neurology 3235 Vollmer Rd 110 Flossmoor IL 60422 330142574 38265 Medical Research Stanford University 3160 Porter Drive Suite 100 Palo Alto CA 943048445 941156365 501c3 870882 Medical Research Sutter East Bay Hospitals PO Box 742585 Los Angeles CA 900742585 941196176 501c3 18193 Medical Research Swedish Health Services PO Box 94085 Seattle WA 981249845 910433740 501c3 6820 Medical Research University of South Florida PO Box 864568 Orlando FL 328864568 593102112 Florida 6883 Medical Research University of Washington 12455 Collections Drive Chicago IL 606930001 916001537 Washington 1006139 Medical Research University of Colorado-Denver PO Box 910238 Denver CO 802910238 846000555 501c3 165384 Medical Research University of Massachusetts Medical School BioLabs Bursar Office Worcester MA 01655 043167352 Massachusetts 27799 Medical Research University of Iowa 2 Gilmore Hall Iowa City IA 52242 426004813 Iowa 19817 Medical Research University of Kentucky Research Foundation PO Box 931113 Cleveland OH 44193 616033693 501c3 33490 Medical Research Unversity of California Box 0897 San Francisco CA 941430897 946002123 501c3 1350081 Medical Research University of Pennsylvania 3451 Walnut St Rm P-221 Philadelphia PA 191046205 231352685 501c3 69371 Medical Research University of California San Diego 9500 Gilman Drive La Jolla CA 920930009 956006144 501c3 21583 Medical Research University of Florida PO Box 113001 Gainesville FL 32611 596002052 501c3 274061 Medical Research University of Nebraska Medical Center 985045 Nebraska Medical Center Omaha NE 681985045 470049123 501c3 151766 Medical Research University of Arizona PO Box 3520 Tucson AZ 857223520 742652689 Arizona 14671 Medical Research University of Maryland Baltimore 220 Arch Street Baltimore MD 212011508 526002033 Maryland 33758 Medical Research University of North Carolina at Chapel Hill 104 Airport Drive Suite 2200 CB1350 Chapel Hill NC 27599 566001393 501c3 481280 Medical Research University of Massachusetts Worcester 55 Lake Avenue North Worcester MA 016550002 043167352 Massachusetts 19535 Medical Research University of California Davis PO Box 989062 West Sacramento CA 957989062 946036494 501c3 26099 Medical Research University of Chicago 5841 S Maryland Ave MC 5030 Chicago IL 60637 362177139 501c3 20352 Medical Research University of California San Francisco 3333 California St Ste 315 San Francisco CA 941430962 946036493 501c3 2628719 Medical Research University of Washington 4333 Brooklyn Ave NE Box 359472 Seattle WA 98195 916001537 Washington 5163 Medical Research University of Pittsburgh PO Box 371220 Pittsburg PA 152517220 250965591 501c3 40621 Medical Research University of Michigan Box 223131 SSC Pittsburgh PA 152512131 386006309 501c3 6926 Medical Research Yale University PO Box 1873 New Haven CT 065081873 060648973 501c3 229386 Medical Research 57 3 Part I Line 2 Subrecipient Monitoring Policy - medical research sub awards - BRI has formal policies and procedures to assure full compliance with applicable policies and laws governing Federal Grants. The Subrecipient Monitoring policy provides assurance that subrecipients comply with Federal Grant regulations. This policy sets the criteria to establish eligibility of subrecipients and requires subrecipients to provide both annual audited financial reports and the annual OMB single audit report that identify compliance with federal laws and regulations. The reports are analyzed with emphasis on auditors assessment of subrecipient internal controls and a standardized Risk Assessment is presented to management on each subrecipient. A Management Letter is issued to each subrecipient showing any findings on their OMB single audit report, and measurements are set for increased monitoring when an elevated level of risk is established. Management has communicated with an educated administrative staff regarding implementation of this policy. The Director of Grants and Contracts is responsible for monitoring subrecipient adherence to financial regulations. The principal investigator is responsible for overseeing the satisfactory performance of the sub-award to ensure that goals are achieved. If there are unusual or unforeseen items, these will be investigated. X true true false true false false false false false false false Carla Greenbaum MD Director 210249 900 23000 6898 241047 Gerald Nepom MD PhD Ex Officio, Director 386087 126458 40496 2592 555633 Joyce Lammert MD PhD Director 441642 119973 18737 110676 11890 702918 John Corman MD Director 466260 17770 46077 21930 552037 Gary Kaplan MD Director 1026920 425070 18737 2051237 41193 3563157 Homer Lane Jr Executive Director and Chief Financial Officer 241807 77885 13000 8394 341086 Jane Buckner MD Research Member 225896 23000 2892 251788 William Kwok PhD Research Member 206984 926 23000 5652 236562 Steven Ziegler PhD Research Member 177752 526 14012 9384 201674 Thomas Wight PhD Research Member 161407 526 23000 14808 199741 Lynn Rose PhD Director Scientific Administration 174803 526 18042 5092 198463 Part I Line 3 Benaroya Ressearch Institute at Virginia Mason relies upon Virginia Mason Medical Centers a related organization Board Compensation and Benefits Committee, a committee composed of independent board members to whom the Board has delegated the authority to approve all compensation and benefits for the executive leaders of the Medical center. to ensure that such benefit plans are market competitive and reasonable, the Committee receives support and advice, including appropriate market comparability data, from an independent compensation consultant with expertise in the health care industry and access to relevant market data. See Schedule O for additional disclosure. Part I Line 4b The Medical Center has a Supplemental Executive Retirement Plan SERP. The SERP is a 457f nonqualified deferred compensation plan pursuant to which plan benefits are subject to a substantial risk of forfeiture, entered into when certain senior executives join the Medical Center. The plan was approved by the Boards Compensation and Benefits Committee, a committee composed of independent board members to whom the board delegates the authority to approve compensation and benefits for the Medical Centers most senior executives. the Committee receives advice from an independent compensation consultant to ensure that compensation and benefits, including the SERP, are market competitve and reasonable. A WA Econ Devel Fin Auth-2012 Series B 911493002 2012-06-01 10390000 See Part VI false true false A 635000 10390348 2550348 7840000 2013 true false true true A false true false true true 0.01290 0.01290 false false true A false true false false false false true A true Part I Line A f Purposes to currently refund WEDFA Series 2006C bonds issued 11/15/2006, and to fund research facility improvements. Part II Line 3 Difference between Part I, column e and Part II, Line 3 is investment earnings. X Advertising 32 147625 Donor valuation false false false Part I Line Column b BRI received two large bulletin displays and 30 poster displays for the BRI Awareness Campaign. Form 990, Part III, Line 1 Benaroya Research Institute at Virginia Mason BRI is a world-renowned medical research institute whose work has resulted in major advances against autoimmune and immune-mediated diseases. One in 20 Americans suffers from one or more autoimmune diseases, such as type 1 diabetes, multiple sclerosis, Crohns disease and rheumatoid arthritis to name a few, and more than one out of every four Americans suffer from diseases of the immune system, such as allergies and asthma. Because these diseases are connected in the way the immune system attacks the body, BRI scientists arent focused on eliminating one or two immune system diseases - they are taking on many more. As a world leader in scientific innovation, BRIs discoveries are having significant impact on people living with these diseases today - by improving the ability to predict disease risk, decreasing disease progression and making therapies safer and better. Form 990, Part III, Line 4 One of the unique qualities of BRI is the close integration of three types of medical research - laboratory research, translational research and clinical research - to improve peoples lives. Our scientists can address both the basic science issues and clinical applications, which is the best way to design studies with the highest potential for success. For BRI, discovery starts in the laboratory. 2014 key outcomes of the Immune Tolerance Network as well as advancements in translational research, diabetes research and other areas of immunological research are highlighted below. Form 990, Part III, Line 4a Funding for the Immune Tolerance Network ITN was awarded to BRIs Dr. Jerry Nepom in 2014 from the National Istitute of Allergy and Infections Disease NIAID of the National Institutes of Health NIH. The 7-year award, totaling 27 million annually supports the ITN, a research consortium established in 1999 with a primary focus on the development of new tolerogenic approaches for the treatement and prevention of disease in three clinical areas asthma and allergic diseases autoimmune diseases and immune-mediated rejection of transplanted solid organs, tissues and cells. As the Prime recipient of this grant BRI is responsible for the management of the overall grant from NIAID including oversight of all aspects of the Networks infrastructure. The major activities in 2014 were diverse, but centered on preserving the ITNs cohesive project focused environment and establishing the framework necessary for successful management of a large cooperative agreement grant. Key outcomes in 2014 include the following 1 Cross Network Integration A top priority in this reporting period was to continue the successful ITN infrastructure with the funding transition over to BRI. This required careful planning and collaboration as the ITNs major centers of operations are geographically diverse, located in Seattle, San Francisco and Bethesda. As such, very few changes were made to the existing network integration, however new relations and vital connections were developed. 2 Operations and Clinical Trial Support The ITN program team at BRI issued 152 subawards in 2014 in support of 23 active ITN clinical trials and numerous supporting ITN mechanistic trials. 3 Supplemental Funding / Partnerships The transition to the cooperative agreement included a significant budget reduction to the ITNs operating budget of approximately 22. To bridge this funding shortage, ITN central administration focused on identifying additional opportunites for supplemental funding and/or funding partnerships. a Supplemental Funding Opportunities The ITN Porgram Team at BRI submitted three supplemental funding requests in 2014. All three were awarded bringing in additional funding to the ITN BRI. The ITN Program Team was also successful in its application to allow pre-clinical work by the ITN. This greatly increased the supplemental funding opportunities to which the ITN program can apply in the future. b Partnerships Finalization of agreements with pharmaceutical partners for partial funding of two ITN studies with NIAID as the clinical sponsor. 4 Publication Activity In 2014, 24 ITN publications were published in prestigious research journals and were presented at domestic and internatioinal research conferences. These publications represented ITN research in all therapeutic focus areas of the ITN Type 1 Diabetes, Transplant, Autoimmune disease and Allergy and Asthma. Form 990, Part III, Line 4b Translational research is a scientific approach that moves finding from the bench to the bedside and back in an expedient and systematic way. It translates new laboratory discoveries quickly into medical practices. Clinician findings are in turn shared with laboratory scientists to bring medical research full circle This transfer of knowledge between laboratory scientists and physicians leads to improved patient care, health and well-being. The research emphasis of the BRI Translational Research Program is the area of immune-mediated disease. BRI scientists and collaborators work together to study blood and serum samples along with medical and demographic data collected from people with autoimmune and immune-mediated diseases. These include multiple sclerosis, type 1 diabetes, lupus, rheumatoid arthritis, inflammatory bowel disease, allergy and asthma. BRI maintains an extensive biorepository with samples dating back to 2000, including 7 disease categories and a biorepository of healthy people for comparison purposes. Advancements in 2014 include the following 1 Scientists made discoveries that led to the isolation of a type of white blood cells that show up only in people with allergic disease. They also began work to find a unique biomarker that initiates and drives allergies. Identifying a biomarker at the top of the allergic chain reaction will help predict the onset of allergy and lead to novel vaccine approaches. This is especially important in at-risk people such as children with a life-threatening food allergy. 2 A new collaboration began in studying a critical question in type I diabetes Why do some people who get type 1 diabetes continue to produce small amounts of insulin over time while others stop Researchers have found at the time of diagnosis with type 1 diabetes that many people continue to produce small amounts of insulin. Since even small amounts of natural insulin production can decrease the long-term effects of diabetes and improve short-term clinical management, scientists search for ways to keep these remaining cells producing insulin. BRIs team of scientists is comparing the genetic and immunological factors that influence levels of insulin production in people with this disease. They intend to utilize this knowledge to develop biomarkers to monitor the immune status of people with type 1 diabetes early in their disease process. The aim would be to design a drug combination that would keep a person with type 1 diabetes producing their own insulin as long as possible. 3 New equipment was purchased that allows acceleration of research discovery through advances in technology. The next generation sequencer, Illumina HiSeq 2500, is Illuminas newest version of the HiSeq instruments and will dramatically increase the sequencing capacity and data yield of the sequencing services offered by the Genomics Core, as well as decrease the cost of sequencing for BRIs labs. Form 990, Part III, Line 4c BRI is dedicated to seeking ways to eliminate type 1 diabetes, while at the same time looking for therapies to prevent, reverse and intervene in the disease at all stages. BRI is an international leader in type 1 diabetes research and has investigated it for more than 30 years, starting with identification of a genetic marker for the disease. Progress in 2014 includes 1 BRI became the TrialNet Hub which supports and advocates for TrialNets clinical centers across the international network, encouraging collaboration and developing processes to streamline recruitment and clinical operations. The TrialNet Network is supported by the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health NIH. The network includes 21 Clinical Centers working in cooperation with more than 200 screening and clinical research sites throughout the United States and seven other countries. TrialNet is dedicated to the study, prevention and early treatment of type 1 diabetes. Clinical trials have identified markers for risk and disease progression in diabetes and are testing therapies to intervene prior to onset of clinical symptoms, by blocking the immune attack on pancreatic beta cells that produce insulin. 2 BRI scientists are investigating the molecular mechanisms of the type 1 diabetes autoimmune response, and of immune interactions with each therapy, to better understand disease progression and uncover new approaches to treatment. These studies are also developing methods to better predict a persons disease risk and provide earlier diagnoses so that patients can begin treatments earlier, at a time when more beta cells remain and more of the insulin production function can be saved. Teams of BRI investigators are developing discovery pipelines for analysis of clinical trial samples to better understand the way different individuals respond to different therapies through interrogation of transcriptional and phenotypic properties of individual immune cells. This information is a cornerstone for tailoring therapy specifically to individuals - the right treatment for the right person at the right time. 3 Through analysis of metabolic and immunological profiles, the Diabetes Research Program and colleagues created new algorithms to track and predict the clinical course of type 1 diabetes, essential for developing innovative prevention and islet preservation therapies. Form 990, Part III, Line 4d Other Advances. 1 Laboratory studies prospered, particularly in discovering new biomarkers and mechanisms of diseases across a broad scope of immunological dysfunction. 2 Studies in allergies identified important specific molecular signals in people with allergy to shrimp and to grass pollen, which will enable personalized monitoring of people with these conditions. 3 Systems Immunology reported several innovative transcriptional profiling studies, including analysis of sepsis and systemic lupus. 4 Researchers identified a novel profile for melanoma that correlates with poor clinical outcomes related to the immunological response to the tumor. 5 Scientists characterized a new type of immunological recognition in patients with rheumatoid arthritis and type 1 diabetes. 6 The Immunology Research Program described complex interactions within T lymphocytes that determine cell lineage and fate, a balance required for normal homeostasis and immune response. 7 A new Computing Cluster for data-intense projects was launched with expanded capabilities for analysis and storage. Form 990, Part VI, Section A, Line 1a The governing body delegates to an Executive Committee comprised of four officers of the Board and the Chairs of each standing Board Committee, the authority of the Board of Directors in the management of the corporation as may be deemed by the Executive Committee to be appropriate, to be exercised in time periods between regularly scheduled meetings of the Board of Directors provided that the Executive Committee has the authority to act only in time sensitive or emergency situations. The Director and the Executive Director of the corporation serve as ex officio members of the Executive Committee without voting rights. The Executive Committee does not have the authority to amend, alter or repeal the bylaws elect, appoint or remove any member of such Executive Committee or any director or officer of the corporation amend the articles of incorporation adopt a plan of merger or adopt a plan of consolidation with another corporation authorize the sale, lease or exchange of all or substantially all the property and assets of the corporation not in the ordinary course of business authorize the voluntary dissolution of the corporation or revoke proceedings therefore adopt a plan for the distribution of the assets of the corporation or amend, alter or repeal any resolution of the Board which by its terms provides that it shall not be amended, altered or repealed by such Executive Committee. The Executive Committee also serves as the planning committee for the Board of Directors and oversees any compliance issues raised by the Board of Directors. Form 990, Part VI, Section A, Line 6, 7 Virginia Mason Health System VMHS is the sole corporate member of Benaroya Research Institute at Virginia Mason BRI. VMHS as the sole voting member has the following approval rights a election or appointment of Directors and Officers of the Board of Directors b removal of Directors and Officers of the Board of Directors including any executive officer of the corporation c approval of all long-range and short-range plans proposed by the Board of Directors d approval of the annual capital and operating budgets proposed by the Board of Directors e approval of the borrowing of funds where the amount borrowed is in excess of Five Hundred Thousand Dollars 500,000 f approval of the sale, lease, exchange, mortgage, pledge or disposal of all or substantially all of the property and assets g approval of all amendments to or repeal of the Agreement Agreement Association or the Bylaws of the corporation h all other rights and powers as specified in the Washington Nonprofit Corporation Act. Form 990, Part VI, Section B, Line 11b The Virginia Mason Health System Audit and Compliance Committee ACC, a committee composed of independent community members has been delegated responsibility for oversight of the annual Form 990 preparation process including a selection, engagement, and review of the performance of the independent tax preparer b review of the annual draft Form 990 tax return, and c recommendation of the final Form 990 tax return for review to the BRI Board of Directors. Annually, at the September meeting, management and the tax preparer provides the ACC with an initial draft of the Form 990 and present an overview of the Form 990 preparation process. The final draft Form 990 is reviewed and approved by the ACC in November followed by a Board review of the final Form 990 prior to filing. The final Form 990 tax return is provided to each member of the Board of Directors via electronic delivery. Form 990, Part VI, Section B, Line 12c The Virginia Mason Health System Governance Committee has been delegated accountability for oversight of the process for disclosure, evaluation and management of conflict of interest involving any member of the Benaroya Research Institute at Virginia Mason BRI Board of Directors, executive leadership or key employees Covered Person. Pursuant to the Conflict of Interest Policy, an annual conflict of interest questionnaire is distributed to all Covered Persons. In addition, a Covered Person has an on-going duty to disclose the existence of a conflict of interest at any time an actual or potential conflict arises. Each Covered Person is required upon appointment and annually thereafter to attest to a statement that affirms that such person has a received a copy of the Conflict of Interest Policy b has read and understands the Policy c has agreed to comply with the Policy and d understands that BRI is a charitable organization and that in order to maintain its federal tax exemption must engage in activities that accomplish its tax-exempt purposes. Written disclosures are reviewed by the Governance Committee to determine if an actual or potential conflict of interest exists and if so, how it should be managed. The Covered Person is informed in writing regarding the determination the Conflict of Interest Management Plan. No Covered Person with an actual or potential conflict of interest shall engage in an activity on BRIs behalf related to the disclossed actual or potential Conflict of Interest unless such activity is permitted by the Conflict of Interest Management Plan or until the Covered Person has undertaken all steps set forth in the Management Plan to manage, reduce or eliminate the conflict. All Covered Person have a duty to disclose the existence of any actual or potential conflict of interest with respect to meeting agenda items. The Conflict of Interest Policy requires that copies of the Conflict of Interest Questionnaire be completed annually by each covered Person and any Conflict of Interest Managemenet Plan be maintained. Form 990, Part VI, Section B, Line 15 The VMHS Compensation and Benefits board Committee, a committee composed solely of independent directors none of whom have a conflict of interest, is accountable for setting reasonable total compensation packages for each executive, officer and key employee Executive consistent with VMHS/BRIs philosophy and principles. The Committee approves annual goals and performance criteria which are used in determining merit increases and variable compensation opportunities. The Committee assesses performance against these goals. The Committee selects and engages a qualified independent compensation consultant to review and analyze the total compensation and benefits packages of the Executives. The Committee as part of its analysis obtsins from the compensation consultant appropriate comparability data including total compensation paid by similarly situated organizations for positions that are functionally comparable to each of the Executives. The Committee will consider the significant terms of the agreement with each Executive including the total compensation to be paid and the employees duties and responsibilities. Consistent with VMHS/BRIs compensation philosophy and principles, the Committee approves total compensation packages for each of the Executives based on information presented to the Committee, reasonableness and the best interest of BRI. The Committees decisions regarding compensation for each Executive are documented in written resolutions and minutes of the Committee. The Committee promptly reports its actions to the VMHS board which reports are reflected in the Boards minutes. The individual positions who were reviewed in 2014 were the Board Director, Carla Greenbaum, BRI Director, and Executive Director and Chief Financial Officer. Form 990, Part VI, Section C, Line 19 The organizations Articles, Bylaws, Conflict of Interest Policy and financial statements are made available upon request. Virginia Mason Health System (VMHS) 1100 Ninth Ave Seattle WA 98101 911351110 Fundraising WA Sec 501c3 7-Support General Pu N/A true Virginia Mason Medical Center 1100 Ninth Ave Seattle WA 98101 910565539 Health Care WA Sec 501c3 3-Hospital VMHS false false false true false false false false false false true true false false true false true true false false Benaroya Research Institute at Virginia Mason 1201 Ninth Avenue Seattle WA 981012795 910653422 0 0 0 61904406 61904406 58586 14647 0 0 0 Virginia Mason Health System 1100 Ninth Avenue Seattle WA 98101 911351110 0 0 0 12874405 12874405 12184 3046 0 0 0 Virginia Mason Institute 1100 Ninth Avenue Seattle WA 98101 263763656 0 0 0 4489124 4489124 4249 1062 0 0 0 Virginia Mason Medical Center 1100 Ninth Avenue Seattle WA 98101 910565539 X 119335 19500 138835 977226184 977365019 924981 231245 0 0 0